Mieloma múltiple en Chile: pasado, presente y futuro del programa nacional de drogas antineoplásicas (PANDA). Revisión de 1.103 pacientes

Background: Multiple myeloma (MM) is one of the most common malignancies found in hematology. Aim: To describe the features of patients with MM and perform a survival analysis according to the different treatment protocols used between 2000 and 2016. Material and Methods: Analysis of the database...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Peña,Camila, Rojas,Christine, Rojas,Hernán, Soto,Pablo, Cardemil,Daniela, Aranda,Sandra, Contreras,Carolina, Roca,Gabriel La, Russo,Moisés, Pérez,Claudio, Lois,Vivianne
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2018
Materias:	Clinical Protocols Cyclophosphamide Multiple Myeloma Thalidomide Transplantation, Autologous
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872018000700869
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872018000700869
record_format	dspace
spelling	oai:scielo:S0034-988720180007008692018-09-26Mieloma múltiple en Chile: pasado, presente y futuro del programa nacional de drogas antineoplásicas (PANDA). Revisión de 1.103 pacientesPeña,CamilaRojas,ChristineRojas,HernánSoto,PabloCardemil,DanielaAranda,SandraContreras,CarolinaRoca,Gabriel LaRusso,MoisésPérez,ClaudioLois,Vivianne Clinical Protocols Cyclophosphamide Multiple Myeloma Thalidomide Transplantation, Autologous Background: Multiple myeloma (MM) is one of the most common malignancies found in hematology. Aim: To describe the features of patients with MM and perform a survival analysis according to the different treatment protocols used between 2000 and 2016. Material and Methods: Analysis of the database of the Chilean national anti-neoplastic drug program. Information was obtained from 1,103 patients, with a median age of 64.5 years (range 27-95) and a male to female ratio of 1:1.2. Results: The mean overall survival (OS) of patients receiving or not receiving Thalidomide was 46 and 30 months, respectively (p < 0.01). The mean OS of patients treated before 2007 (treated with melphalan and prednisone) and between 2007 and 2012 (treated with thalidomide and dexamethasone) was 36 and 48 months respectively. In the group starting in 2013 (treated with cyclophosphamide, thalidomide and dexamethasone) the median survival had not been reached at 20 months of follow up (p = 0.01 for all comparisons). Autologous transplantation (AT) was carried out in only 18% of the eligible patients. The median OS of the patients who receive an AT had not been reached at 48 month compared with 36 month among those who did not received the procedure (p < 0.01). Conclusions: Even though overall survival has improved with time, new drugs must be introduced in our protocols to obtain similar results to those obtained worldwide.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.146 n.7 20182018-07-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872018000700869es10.4067/s0034-98872018000700869
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Clinical Protocols Cyclophosphamide Multiple Myeloma Thalidomide Transplantation, Autologous
spellingShingle	Clinical Protocols Cyclophosphamide Multiple Myeloma Thalidomide Transplantation, Autologous Peña,Camila Rojas,Christine Rojas,Hernán Soto,Pablo Cardemil,Daniela Aranda,Sandra Contreras,Carolina Roca,Gabriel La Russo,Moisés Pérez,Claudio Lois,Vivianne Mieloma múltiple en Chile: pasado, presente y futuro del programa nacional de drogas antineoplásicas (PANDA). Revisión de 1.103 pacientes
description	Background: Multiple myeloma (MM) is one of the most common malignancies found in hematology. Aim: To describe the features of patients with MM and perform a survival analysis according to the different treatment protocols used between 2000 and 2016. Material and Methods: Analysis of the database of the Chilean national anti-neoplastic drug program. Information was obtained from 1,103 patients, with a median age of 64.5 years (range 27-95) and a male to female ratio of 1:1.2. Results: The mean overall survival (OS) of patients receiving or not receiving Thalidomide was 46 and 30 months, respectively (p < 0.01). The mean OS of patients treated before 2007 (treated with melphalan and prednisone) and between 2007 and 2012 (treated with thalidomide and dexamethasone) was 36 and 48 months respectively. In the group starting in 2013 (treated with cyclophosphamide, thalidomide and dexamethasone) the median survival had not been reached at 20 months of follow up (p = 0.01 for all comparisons). Autologous transplantation (AT) was carried out in only 18% of the eligible patients. The median OS of the patients who receive an AT had not been reached at 48 month compared with 36 month among those who did not received the procedure (p < 0.01). Conclusions: Even though overall survival has improved with time, new drugs must be introduced in our protocols to obtain similar results to those obtained worldwide.
author	Peña,Camila Rojas,Christine Rojas,Hernán Soto,Pablo Cardemil,Daniela Aranda,Sandra Contreras,Carolina Roca,Gabriel La Russo,Moisés Pérez,Claudio Lois,Vivianne
author_facet	Peña,Camila Rojas,Christine Rojas,Hernán Soto,Pablo Cardemil,Daniela Aranda,Sandra Contreras,Carolina Roca,Gabriel La Russo,Moisés Pérez,Claudio Lois,Vivianne
author_sort	Peña,Camila
title	Mieloma múltiple en Chile: pasado, presente y futuro del programa nacional de drogas antineoplásicas (PANDA). Revisión de 1.103 pacientes
title_short	Mieloma múltiple en Chile: pasado, presente y futuro del programa nacional de drogas antineoplásicas (PANDA). Revisión de 1.103 pacientes
title_full	Mieloma múltiple en Chile: pasado, presente y futuro del programa nacional de drogas antineoplásicas (PANDA). Revisión de 1.103 pacientes
title_fullStr	Mieloma múltiple en Chile: pasado, presente y futuro del programa nacional de drogas antineoplásicas (PANDA). Revisión de 1.103 pacientes
title_full_unstemmed	Mieloma múltiple en Chile: pasado, presente y futuro del programa nacional de drogas antineoplásicas (PANDA). Revisión de 1.103 pacientes
title_sort	mieloma múltiple en chile: pasado, presente y futuro del programa nacional de drogas antineoplásicas (panda). revisión de 1.103 pacientes
publisher	Sociedad Médica de Santiago
publishDate	2018
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872018000700869
work_keys_str_mv	AT penacamila mielomamultipleenchilepasadopresenteyfuturodelprogramanacionaldedrogasantineoplasicaspandarevisionde1103pacientes AT rojaschristine mielomamultipleenchilepasadopresenteyfuturodelprogramanacionaldedrogasantineoplasicaspandarevisionde1103pacientes AT rojashernan mielomamultipleenchilepasadopresenteyfuturodelprogramanacionaldedrogasantineoplasicaspandarevisionde1103pacientes AT sotopablo mielomamultipleenchilepasadopresenteyfuturodelprogramanacionaldedrogasantineoplasicaspandarevisionde1103pacientes AT cardemildaniela mielomamultipleenchilepasadopresenteyfuturodelprogramanacionaldedrogasantineoplasicaspandarevisionde1103pacientes AT arandasandra mielomamultipleenchilepasadopresenteyfuturodelprogramanacionaldedrogasantineoplasicaspandarevisionde1103pacientes AT contrerascarolina mielomamultipleenchilepasadopresenteyfuturodelprogramanacionaldedrogasantineoplasicaspandarevisionde1103pacientes AT rocagabriella mielomamultipleenchilepasadopresenteyfuturodelprogramanacionaldedrogasantineoplasicaspandarevisionde1103pacientes AT russomoises mielomamultipleenchilepasadopresenteyfuturodelprogramanacionaldedrogasantineoplasicaspandarevisionde1103pacientes AT perezclaudio mielomamultipleenchilepasadopresenteyfuturodelprogramanacionaldedrogasantineoplasicaspandarevisionde1103pacientes AT loisvivianne mielomamultipleenchilepasadopresenteyfuturodelprogramanacionaldedrogasantineoplasicaspandarevisionde1103pacientes
_version_	1718437013957378048

Mieloma múltiple en Chile: pasado, presente y futuro del programa nacional de drogas antineoplásicas (PANDA). Revisión de 1.103 pacientes

Ejemplares similares